On Friday, Shares of Berkshire Hathaway Inc. (NYSE:BRK.B), gained 0.44% to $142.65.
Berkshire’s operating results for the second quarter and first six months of 2015 are summarized in the following paragraphs. However, we urge investors and reporters to read our 10-Q, which has been posted at www.berkshirehathaway.com. The limited information that follows in this press release is not adequate for making an informed investment judgment.
Earnings of Berkshire Hathaway Inc. and its merged auxiliaries for the second quarter and first six months of 2015 and 2014 are summarized below. Earnings are stated on an after-tax basis. (Dollar amounts are in millions, except for per share amounts).
Berkshire Hathaway, Inc. is a publicly owned investment manager. Through its auxiliaries, the firm primarily engages in the insurance and reinsurance of property and casualty risks business. Berkshire Hathaway was founded in 1889 and is based in Omaha, Nebraska.
Shares of Health Care REIT, Inc. (NYSE:HCN), inclined 67.96% to $0.12, during its last trading session.
Health Care REIT, declared a cash dividend for the quarter ended June 30, 2015 of $0.825 per share. The dividend will be the company’s 177th successive quarterly payment, payable August 20, 2015, to stockholders of record on August 11, 2015.
Health Care REIT, Inc. is an independent equity real estate investment trust. The firm engages in acquiring, planning, developing, managing, repositioning and monetizing of real estate assets. It primarily invests in the real estate markets of the United States. The firm primarily invests in senior living and health care properties.
At the end of Friday’s trade, Shares of Eli Lilly and Co (NYSE:LLY), gained 83.91% to $1.06.
To emphasize the importance of a support system in diabetes administration, Lilly Diabetes and NASCAR XFINITY Series driver Ryan Reed will kick off the My Diabetes Pit Crew Sweepstakes recently in association with the Lilly Diabetes 250, the NASCAR XFINITY Series race in Indianapolis. The sweepstakes hopes to encourage people with diabetes to acknowledge the people who have supported them throughout their diabetes journey.
A total of 24 entrants will be chosen at random to be honorary members of Reed’s pit crew during the three NASCAR XFINITY Series races in November, which is American Diabetes Month. Eight people will be chosen for each race. Winners will have the option to have their names displayed on the fire suit worn by a member of Reed’s racing pit crew and their pictures to appear in a mosaic on Reed’s pit wall. Winners will receive educational materials from Lilly to assist them manage their diabetes, together with a congratulatory phone call from Reed. Following the November races, winners will receive their personalized fire suit patch signed by Reed.
Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency.
Finally, Orexigen Therapeutics, Inc. (NASDAQ:OREX), ended its last trade with 3.24% gain, and closed at $3.50.
Orexigen Therapeutics declared business and financial results for the second quarter ended June 30, 2015.
“We are very happy with the strong growth of Contrave prescription volumes, driven by a product profile that is resonating with physicians and patients and by the steady, market-leading share of voice offered by Takeda,” said Mike Narachi, CEO of Orexigen.
Financial results for the three months ended June 30, 2015
For the three months ended June 30, 2015, Orexigen stated a net loss of $22.5 million, or $0.18 per share, as contrast to a net loss of $24.5 million, or $0.21 per share, for the second quarter of 2014.
Orexigen stated second quarter revenue of $5.2 million, counting $3.1 million in royalties earned on U.S. net sales of Contrave of $16.0 million recorded by Orexigen’s partner for North America, Takeda Pharmaceuticals.
Total operating expenses for the second quarter of 2015 were $25.9 million contrast to $23.7 million for the second quarter of 2014. The enhance in operating expense was driven by an enhance in general and administrative expense, primarily for marketing and consulting costs and stock compensation expense.
As of June 30, 2015, Orexigen had $71.6 million in cash and cash equivalents and an additional $103.5 million in marketable securities, for a total of $175.1 million.
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products in the United States. The company offers Contrave for the treatment of obesity.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
